This is theKitchen Sink For Cell Medica

Heading one

Heading Two

Heading Three

Heading Four

Heading Five
Heading Six

We are developing a range of innovative Chimeric Antigen Receptor (CAR) NKT cell products that allow for multiple target-specific constructs in both the allogeneic and autologous settings. NKT cells contain an invariant T cell receptor which confers distinct advantages over T-cells in the allogeneic (off-the-shelf) setting. Our novel constructs incorporate IL-15 to improve persistence and expansion.

  • List Item 1
  • List Item 2
  • List Item 3
  • List Item 4
  1. List Item 1
  2. List Item 2
  3. List Item 3
  4. List Item $

Example Image WithText

We are developing a range of innovative Chimeric Antigen Receptor (CAR) NKT cell products that allow for multiple target-specific constructs in both the allogeneic and autologous settings. NKT cells contain an invariant T cell receptor which confers distinct advantages over T-cells in the allogeneic (off-the-shelf) setting. Our novel constructs incorporate IL-15 to improve persistence and expansion.

We are developing a range of innovative Chimeric Antigen Receptor (CAR) NKT cell products that allow for multiple target-specific constructs in both the allogeneic and autologous settings. NKT cells contain an invariant T cell receptor which confers distinct advantages over T-cells in the allogeneic (off-the-shelf) setting. Our novel constructs incorporate IL-15 to improve persistence and expansion.

Example Image With Text 2

We are developing a range of innovative Chimeric Antigen Receptor (CAR) NKT cell products that allow for multiple target-specific constructs in both the allogeneic and autologous settings. NKT cells contain an invariant T cell receptor which confers distinct advantages over T-cells in the allogeneic (off-the-shelf) setting. Our novel constructs incorporate IL-15 to improve persistence and expansion.

We are developing a range of innovative Chimeric Antigen Receptor (CAR) NKT cell products that allow for multiple target-specific constructs in both the allogeneic and autologous settings. NKT cells contain an invariant T cell receptor which confers distinct advantages over T-cells in the allogeneic (off-the-shelf) setting. Our novel constructs incorporate IL-15 to improve persistence and expansion.

Example Image With Text 3

We are developing a range of innovative Chimeric Antigen Receptor (CAR) NKT cell products that allow for multiple target-specific constructs in both the allogeneic and autologous settings. NKT cells contain an invariant T cell receptor which confers distinct advantages over T-cells in the allogeneic (off-the-shelf) setting. Our novel constructs incorporate IL-15 to improve persistence and expansion.

We are developing a range of innovative Chimeric Antigen Receptor (CAR) NKT cell products that allow for multiple target-specific constructs in both the allogeneic and autologous settings. NKT cells contain an invariant T cell receptor which confers distinct advantages over T-cells in the allogeneic (off-the-shelf) setting. Our novel constructs incorporate IL-15 to improve persistence and expansion.

Example Image With Text 4

We are developing a range of innovative Chimeric Antigen Receptor (CAR) NKT cell products that allow for multiple target-specific constructs in both the allogeneic and autologous settings. NKT cells contain an invariant T cell receptor which confers distinct advantages over T-cells in the allogeneic (off-the-shelf) setting. Our novel constructs incorporate IL-15 to improve persistence and expansion.

We are developing a range of innovative Chimeric Antigen Receptor (CAR) NKT cell products that allow for multiple target-specific constructs in both the allogeneic and autologous settings. NKT cells contain an invariant T cell receptor which confers distinct advantages over T-cells in the allogeneic (off-the-shelf) setting. Our novel constructs incorporate IL-15 to improve persistence and expansion.

Example Image With Text 5

We are developing a range of innovative Chimeric Antigen Receptor (CAR) NKT cell products that allow for multiple target-specific constructs in both the allogeneic and autologous settings. NKT cells contain an invariant T cell receptor which confers distinct advantages over T-cells in the allogeneic (off-the-shelf) setting. Our novel constructs incorporate IL-15 to improve persistence and expansion.

We are developing a range of innovative Chimeric Antigen Receptor (CAR) NKT cell products that allow for multiple target-specific constructs in both the allogeneic and autologous settings. NKT cells contain an invariant T cell receptor which confers distinct advantages over T-cells in the allogeneic (off-the-shelf) setting. Our novel constructs incorporate IL-15 to improve persistence and expansion.

Full Width Text With Link / Background

We strive to be the leading provider of cellular immunotherapy products for the treatment of blood- and solid cancers (oncology). Our mission is to develop products and therapies that will transform the lives of patients.

Our products harness the natural power of the human immune system to fight cancer without the risk of severe side effects that come with conventional anti-viral drugs or chemotherapy.

As we grow, we are looking for people who share our passion and want to be part of an exceptional team who are working to unlock the full potential of this powerful new scientific technology. We know that it is only by having right people working together in the right environment, that we will achieve our goal.

Full Width Text With No Background / Link

We strive to be the leading provider of cellular immunotherapy products for the treatment of blood- and solid cancers (oncology). Our mission is to develop products and therapies that will transform the lives of patients.

Our products harness the natural power of the human immune system to fight cancer without the risk of severe side effects that come with conventional anti-viral drugs or chemotherapy.

As we grow, we are looking for people who share our passion and want to be part of an exceptional team who are working to unlock the full potential of this powerful new scientific technology. We know that it is only by having right people working together in the right environment, that we will achieve our goal.

Text & Image Slider

Alongside world-class research institutions and industry leaders, we are developing next-generation cellular therapies to transform cancer treatment.

Baylor College of Medicine

Cell Medica and the Centre for Cell and Gene Therapy (CAGT) at Baylor College of Medicine have an ongoing R&D partnership that also includes University of North Carolina (UNC), signed in April 2016. Baylor is a world class centre with significant expertise in cell and gene therapy across basic research, translational and clinical trials.

Our collaboration focuses on the development of our CAR-NKT platform through pre-clinical and clinical development. The team, led by Prof Leonid Metelitsa and Dr Andras Heczey, are working to advance the pioneering CAR-NKT platform, a first-in-class innovative CAR T cell therapy.

Cell Medica has exclusive rights to the CAR-NKT Intellectual Property (IP) generated at Baylor.

Testing Another Slider

Cell Medica and the Centre for Cell and Gene Therapy (CAGT) at Baylor College of Medicine have an ongoing R&D partnership that also includes University of North Carolina (UNC), signed in April 2016. Baylor is a world class centre with significant expertise in cell and gene therapy across basic research, translational and clinical trials.

Our collaboration focuses on the development of our CAR-NKT platform through pre-clinical and clinical development. The team, led by Prof Leonid Metelitsa and Dr Andras Heczey, are working to advance the pioneering CAR-NKT platform, a first-in-class innovative CAR T cell therapy.

Cell Medica has exclusive rights to the CAR-NKT Intellectual Property (IP) generated at Baylor.

Text & Image Slider Force Enlargement

Alongside world-class research institutions and industry leaders, we are developing next-generation cellular therapies to transform cancer treatment.

Baylor College of Medicine

Cell Medica and the Centre for Cell and Gene Therapy (CAGT) at Baylor College of Medicine have an ongoing R&D partnership that also includes University of North Carolina (UNC), signed in April 2016. Baylor is a world class centre with significant expertise in cell and gene therapy across basic research, translational and clinical trials.

Our collaboration focuses on the development of our CAR-NKT platform through pre-clinical and clinical development. The team, led by Prof Leonid Metelitsa and Dr Andras Heczey, are working to advance the pioneering CAR-NKT platform, a first-in-class innovative CAR T cell therapy.

Cell Medica has exclusive rights to the CAR-NKT Intellectual Property (IP) generated at Baylor.

Testing Another Slider

Cell Medica and the Centre for Cell and Gene Therapy (CAGT) at Baylor College of Medicine have an ongoing R&D partnership that also includes University of North Carolina (UNC), signed in April 2016. Baylor is a world class centre with significant expertise in cell and gene therapy across basic research, translational and clinical trials.

Our collaboration focuses on the development of our CAR-NKT platform through pre-clinical and clinical development. The team, led by Prof Leonid Metelitsa and Dr Andras Heczey, are working to advance the pioneering CAR-NKT platform, a first-in-class innovative CAR T cell therapy.

Cell Medica has exclusive rights to the CAR-NKT Intellectual Property (IP) generated at Baylor.

Text & Image Slider Images Left

Alongside world-class research institutions and industry leaders, we are developing next-generation cellular therapies to transform cancer treatment.

Testing Another Slider

Cell Medica and the Centre for Cell and Gene Therapy (CAGT) at Baylor College of Medicine have an ongoing R&D partnership that also includes University of North Carolina (UNC), signed in April 2016. Baylor is a world class centre with significant expertise in cell and gene therapy across basic research, translational and clinical trials.

Our collaboration focuses on the development of our CAR-NKT platform through pre-clinical and clinical development. The team, led by Prof Leonid Metelitsa and Dr Andras Heczey, are working to advance the pioneering CAR-NKT platform, a first-in-class innovative CAR T cell therapy.

Cell Medica has exclusive rights to the CAR-NKT Intellectual Property (IP) generated at Baylor.

Testing Another Slider 2

Cell Medica and the Centre for Cell and Gene Therapy (CAGT) at Baylor College of Medicine have an ongoing R&D partnership that also includes University of North Carolina (UNC), signed in April 2016. Baylor is a world class centre with significant expertise in cell and gene therapy across basic research, translational and clinical trials.

Our collaboration focuses on the development of our CAR-NKT platform through pre-clinical and clinical development. The team, led by Prof Leonid Metelitsa and Dr Andras Heczey, are working to advance the pioneering CAR-NKT platform, a first-in-class innovative CAR T cell therapy.

Cell Medica has exclusive rights to the CAR-NKT Intellectual Property (IP) generated at Baylor.